Quantifying Binding Kinetics in Complex Serum

The Serum Challenge

A binder that performs beautifully in phosphate-buffered saline (PBS) may fail completely in serum. Complex biological fluids contain thousands of proteins, lipids, and metabolites — any of which can interfere with binding through competitive, allosteric, or non-specific mechanisms.

Non-Specific Binding (NSB)

NSB is the most common failure mode in serum. It manifests as:

• High reference channel signal in SPR/BLI — the analyte sticks to the sensor surface even without immobilized target.
• Super-stoichiometric binding in SEC — more analyte bound than the stoichiometry allows.
• Loss of activity over time — the binder is sequestered by serum components.

Mitigation Strategies

1. Surface chemistry optimization — PEGylated sensor surfaces, carboxymethyl dextran, and polycarboxylate coatings reduce NSB.
2. Buffer additives — 0.05% Tween-20, 1 mg/mL BSA, or 0.5 M NaCl can outcompete weak NSB interactions.
3. Binder engineering — reducing surface hydrophobicity and optimizing charge distribution at the binder surface.

Kinetic Analysis in Serum

Even without NSB, serum components affect binding kinetics:

• Increased viscosity slows diffusion, reducing the apparent association rate (kₐ).
• Crowding agents can stabilize or destabilize the bound complex depending on the interface.
• Albumin and immunoglobulins — the most abundant serum proteins — rarely interfere directly but contribute to crowding effects.

Correction Approaches

• Viscosity correction — normalize kₐ by the relative viscosity of serum vs. buffer (∼1.3 for 50% human serum).
• Serum calibration curves — establish baseline kinetic parameters in buffer, then measure the same interaction in serum to quantify matrix effects.
• Depleted serum controls — use albumin/IgG-depleted serum to isolate specific interference sources.

Case Study: EGFR Binder in 50% Serum

A de novo EGFR binder designed by WeaveSeq showed:

The PEGylated sensor surface recovered most of the binding signal, confirming that NSB to the sensor — not serum protein interference with the binder itself — was the primary source of signal degradation.

Best Practices

1. Always include a serum titration — measure binding at 0%, 10%, 25%, 50%, and 90% serum to quantify matrix effects.
2. Report both buffer and serum kinetics — buffer kinetics demonstrate intrinsic affinity; serum kinetics demonstrate practical utility.
3. Use orthogonal methods — confirm serum SPR/BLI results with SEC or ITC where possible.

---

WeaveSeq's validation protocols include standardized serum interference panels. Start a project to learn more.